Mafoprazine

From Wikipedia the free encyclopedia

Mafoprazine
Clinical data
Trade namesMafropan
AHFS/Drugs.comMonograph
Identifiers
  • N-[4-[3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy]-3-methoxyphenyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H28FN3O3
Molar mass401.482 g·mol−1
3D model (JSmol)
  • COC1=C(OCCCN2CCN(CC2)C3=C(F)C=CC=C3)C=CC(NC(C)=O)=C1
  • InChI=1S/C22H28FN3O3/c1-17(27)24-18-8-9-21(22(16-18)28-2)29-15-5-10-25-11-13-26(14-12-25)20-7-4-3-6-19(20)23/h3-4,6-9,16H,5,10-15H2,1-2H3,(H,24,27) checkY
  • Key:PHOCQBYGUQPMIB-UHFFFAOYSA-N checkY

Mafoprazine is an antipsychotic of the phenylpiperazine class which is used in veterinary medicine.[1] Intramuscular injections of mafoprazine mesylate are used for the sedation of pigs either on its own,[2] or in combination with sodium pentobarbital[3] or thiopental.[4]

Pharmacology[edit]

Mafoprazine
Site Ki (nM) Species Ref
D2 10.7 Rat [5][6]
α1 12.7 Rat [5][6]
α2 101.0 Rat [5][6]

It demonstrates activity as a D2 dopamine receptor antagonist, an α1 adrenergic receptor antagonist, and an α2 adrenergic receptor agonist.[5]

The affinity of mafoprazine for D2 dopamine receptors is 6 and 16 times lower than that of chlorpromazine and haloperidol, respectively, but 2 times higher than that of azaperone.[5]

The Ki for various receptors was determined using rat neuronal receptor binding assays.[citation needed]

History[edit]

Mafoprazine was first synthesized in 1988.[5] It is sold as Mafropan® by DS Pharma Animal Health Co. Ltd., Osaka, Japan.

References[edit]

  1. ^ "Mafoprazine | Chemical Substance Information | J-GLOBAL". jglobal.jst.go.jp.
  2. ^ Heishima, Kazuki; Kuo, Kendon; Kimura, Masashi; Mori, Takashi (2019). "Animal Lymphocyte Metaphase Chromosome Preparation". Radiation Cytogenetics. Methods in Molecular Biology. Vol. 1984. pp. 7–22. doi:10.1007/978-1-4939-9432-8_2. ISBN 978-1-4939-9430-4. PMID 31267415. S2CID 195787061.
  3. ^ Azizi, AFN; Miyazaki, R; Yumito, T; Ohashi, Y; Uno, S; Miyajima, U; Kumamoto, M; Uchiyama, S; Yasuda, M (1 January 2018). "Effect of maternal supplementation with seaweed powder on immune status of liver and lymphoid organs of piglets". The Journal of Veterinary Medical Science. 80 (1): 8–12. doi:10.1292/jvms.17-0537. PMC 5797852. PMID 29142150.
  4. ^ Umeyama, Kazuhiro; Watanabe, Kota; Watanabe, Masahito; Horiuchi, Keisuke; Nakano, Kazuaki; Kitashiro, Masateru; Matsunari, Hitomi; Kimura, Tokuhiro; Arima, Yoshimi; Sampetrean, Oltea; Nagaya, Masaki; Saito, Masahiro; Saya, Hideyuki; Kosaki, Kenjiro; Nagashima, Hiroshi; Matsumoto, Morio (14 April 2016). "Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts". Scientific Reports. 6 (1): 24413. Bibcode:2016NatSR...624413U. doi:10.1038/srep24413. PMC 4830947. PMID 27074716. S2CID 22352477.
  5. ^ a b c d e f Fukuchi, Isao; Kawashima, Kazutaka; Matsuoka, Yuzo; Ishida, Ryuichi (1988). "Neurochemical study of mafoprazine, a new phenylpiperazine derivative". The Japanese Journal of Pharmacology. 47 (1): 51–61. doi:10.1254/jjp.47.51. PMID 3411821. S2CID 13158367.
  6. ^ a b c "NCATS Inxight Drugs — MAFOPRAZINE". drugs.ncats.io.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mafoprazine&oldid=1212340550"